Which study reported OS results in favor of axitinib plus pembrolizumab, ultimately obtaining the lowest hazard ratio observed for survival in any phase 3 trial, a benefit seen across prognostic risk groups and regardless of PD‑L1 expression...
Which study reported OS results in favor of axitinib plus pembrolizumab, ultimately obtaining the lowest hazard ratio observed for survival in any phase 3 trial, a benefit seen across prognostic risk groups and regardless of PD‑L1 expression...
Which study reported OS results...